Publications Reliability of Histologic Assessment for NAFLD and Development of an Expanded NAFLD Activity Score Citation Rish K Pai, Vipul Jairath, Malcolm Hogan, Guangyong Zou, Oyedele A Adeyi, Quentin M Anstee, Bashar A Aqel, Cynthia Behling, Elizabeth J Carey, Andrew D Clouston, Kathleen Corey, Brian G Feagan, David E Kleiner, Christopher Ma, Stefanie C McFarlane, Mazen Noureddin, Vlad Ratziu, Mark A Valasek, Zobair M Younossi, Stephen A Harrison, Rohit Loomba. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology. 2022 Mar 25. DOI: 10.1002/hep.32475. Online ahead of print. PMID: 35332569 Abstract Background and aims: The NASH Clinical Research Network histologic scoring system, the gold-standard NASH histology assessment for clinical trials, has demonstrated intrarater and interrater variability. An expert panel in a previous systematic Research and Development/University of California Los Angeles (RAND/UCLA) study determined that existing histologic scoring systems do not fully capture NASH disease activity and fibrosis, and standardized definitions of histologic features are needed. We evaluated the reliability of existing and alternate histologic measures and their correlations with a disease activity visual analog scale to propose optimal components for an expanded NAFLD activity score (NAS). Tags Biopsy, Fibrosis, Liver, NAFLD, Non-alcoholic Fatty Liver Disease, Pathology Read More